ESMO Guidance for Reporting Oncology real-World evidence (GROW)Luís Castelo-Branco, Miriam Koopman, Urania Dafni et al.|Annals of Oncology|2023Cited by 209
Predicting response and survival in chemotherapy-treated triple-negative breast cancerAleix Prat, Emilio Alba, Aňa Lluch et al.|British Journal of Cancer|2014Cited by 113
Abstract P3-07-14: Prosigna® intrinsic subtyping predicts response to neoadjuvant combination therapy in study that includes herceptin within HER2+ (IHC) patientsÁngela Santonja, Emilio Alba, Nuria Ribelles et al.|Cancer Research|2016Cited by 1